Legend Biotech Corporation shares have plunged 34.5% after briefly rallying to $24.3 on November 9, partly amid the broader selloff in AI-related stocks. I continue to take advantage of market pessimism by steadily accumulating LEGN. Sales of LEGN's blockbuster, Carvykti, developed jointly with J&J, increased 8.1% quarter-on-quarter to $710 million.

